AbstrACt
Purpose In 1998, the AIDS Therapy Evaluation in the Netherlands (ATHENA) national observational HIV cohort was established to demonstrate the lifesaving effectiveness of triple combination antiretroviral therapy, including HIV-protease inhibitors, that had recently been made available for clinical use. Subsequently, the HIV Monitoring Foundation was established by the Dutch Ministry of Health, Welfare and Sport to continue ATHENA as an open cohort in order to continue the registration and monitoring of all HIV-positive people as an integral part of HIV care in all 26 HIV treatment centres in the Netherlands. Participants To date, a total of 25 036 participants have been enrolled in the cohort, with 263 600 person-years of follow-up. As of 1 January 2017, 19 035 HIV-1-positive participants were known to be in care: 18 824 adults (81% men and 19% women) and 211 children (47% boys and 53% girls). The remaining 6001 participants had either died (46%), were lost to care (29%) or had moved abroad (25%). Findings to date Today, with over 20 years of follow-up, the ATHENA cohort has provided extensive knowledge on HIV treatment, comorbidities and coinfections and created insight into the transmission dynamics of the HIV epidemic. Future plans ATHENA continues to enrol and monitor HIV positive people entering HIV care in the Netherlands. Future research will continue to provide tangible input into HIV care and prevention policies in the Netherlands and internationally.
IntroduCtIon
The AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort is a nationwide observational cohort that monitors HIV management of all HIV-positive people in HIV care in the Netherlands, since the introduction of highly active antiretroviral therapy (HAART nowadays known as combination antiretroviral therapy (cART)) when the first HIV-protease inhibitor (PI) became available. As a result of the decisive action taken by the late Dutch Minister of Health, Welfare and Sport, Professor Dr Els Borst, cART including this PI became available in the Netherlands in September 1996. However, its swift introduction was conditional on the following: only specialised HIV treatment centres were allowed to prescribe cART, and the effectiveness of cART in clinical practice had to be demonstrated. Accordingly, in November 1997, the Dutch National Health Insurance Council provided a grant to the Academic Medical Center of the University of Amsterdam for the ATHENA cohort to assess the effectiveness of cART in clinical practice. The ATHENA cohort was highly successfully in its mission to 'assess the implications for the course of HIV disease, public health and health care of the introduction of new anti-HIV treatment, the monitoring of that new treatment, as well as the economic costs and benefits of the new treatment'.
Subsequently 2 3 Because data collection on Curacao is not part of the ATHENA cohort, this will not be discussed further as it is beyond the scope of this profile. eligibility criteria and recruitment Registration with SHM and enrolment in ATHENA is an ongoing process. First, all newly diagnosed HIV-positive adults and children entering HIV care are registered at SHM by their treating HIV physician. Subsequently, enrolment in the ATHENA cohort is based on an opt-out principle (see also: Ethical approval and Patient consent). By 1 January 2017, SHM had registered a cumulative number of 25 564 HIV-positive adults and children in the Netherlands, of whom 525 (2.1%) adults and 3 (1.2%) children opted-out of further data collection 4 (table 1) . Subsequently, a total of 25 036 (97.9%) adults and children were enrolled in the cohort with a total follow-up time of 263 600 person-years. The majority were HIV-1 positive (n=24 773; 98.9%); the remainder were HIV-2 positive (n=97; 0.4%) or had HIV-1 and HIV-2 dual infection (n=60; 0.2%) or no serological results (n=106; 0.4%).
At initiation, the cohort was approved by the institutional review board of all participating centres. HIV-positive people in care can opt-out after being informed by their treating physician of the purpose of collection of data. Data are pseudonymised before being provided to investigators and may be used for scientific purposes. A designated quality management coordinator safeguards compliance with the European General Data Protection Regulation. 5 Methods of data collection and follow-up Detailed clinical and laboratory data from all enrolled HIV-positive adults and children are extracted from medical records by trained data collectors in cooperation with the responsible HIV-treating physician using an extensive, standardised protocol. In addition, 13 laboratories electronically forward test results directly to SHM. 
Open access
The ATHENA cohort does not dictate scheduled study visits, examinations or blood work; that is, the frequency and type of visits, examinations and laboratory measurements depend on both the participant and physician.
Consequently, the cohort reflects routine HIV care, and follow-up time in the cohort is equal to follow-up time in HIV care in the Netherlands. If participants move from one HIV treatment centre to another, this transfer Open access is registered, and follow-up continues at the new centre. Likewise, children who transfer from paediatric to adult HIV care remain in follow-up. Participant registration and data collection are organised on a national level. When transferring to a new treatment centre within the Netherlands-in case of transfer from paediatric to adult care, or transfer to another treatment centre-the participants' study identifier is retained, and data collection is continued without interruption. Key epidemiological data are collected from all HIV-positive people on registration at SHM. For national HIV surveillance, SHM reports these statistics to the Centrum voor Infectieziektebestrijding (CIb; Centre for Infectious Disease Control) of the Rijksinstituut voor Volksgezondheid en Milieu (RIVM; National Institute for Public Health and the Environment). Through the RIVM-CIb, SHM also contributes to European HIV surveillance by the European Centre for Disease Prevention and Control (ECDC). 6 After registration at SHM and enrolment in ATHENA, clinical and laboratory data from all adults and children are prospectively collected as long as the patients remain in care in a Dutch HIV treatment centre. The date of HIV diagnosis is usually retrieved from the letter of referral from the general practitioner or sexually transmitted infections clinic, or from health records in the HIV treatment centre, and can be self-reported on entry to care if there is no documentation available. All reported HIV tests, test dates and test outcomes (including the last negative HIV tests) are captured in the cohort. The data collection process is dynamic and has evolved over the years, with additions and removals of data items based on novel insights and clinical and epidemiological requirements. While the standard data collection protocol is already comprehensive, specific protocols exist for pregnant women, children and hepatitis B (HBV) and hepatitis C (HCV) virus coinfection. A complete overview of the items that are collected can be found online. 7 On enrolment, the following information is collected: demographics, history of HIV infection (including the possibility of a primary infection), most likely route of HIV acquisition, smoking, alcohol and drug use. At each visit, the following information is collected: body weight and height, blood pressure, Centers for Disease Control and Prevention classification for HIV infection -Category B (CDC-B) and Centers for Disease Control and Prevention classification for HIV infection -Category C (CDC-C) events, 8 antiretroviral therapy, adverse events (when resulting in a change of antiretroviral treatment or when specified in the protocol 7 ), non-AIDS comorbidities (particularly diabetes mellitus, cardiovascular disease, chronic kidney disease and non-AIDS malignancies), comedication and participant's participation in clinical trials or studies. All available laboratory results are collected at each visit: virology, immunology, chemistry, haematology and results on viral coinfections or sexually transmitted diseases. HIV genome sequences and HCV and HBV genotypes are collected when available.
Furthermore, additional liver diagnostic information (fibroscan, liver pathology and radiology), and additional information concerning HBV and HCV coinfection (HBV vaccination, hepatocellular carcinoma screening, diagnosis and treatment, and virological response to antiviral treatment) are collected. During pregnancy, obstetric and pregnancy-related data are also collected. If applicable, the cause of death is classified by the physician, using the Coding of Death format. 9 For children, additional information is collected at enrolment and subsequent visits: nationality, country of birth, HIV status of both parents, HIV status of their siblings, perinatal information, head circumference, puberty stage, Centers for Disease Control and Prevention classification for HIV infection -Category A (CDC-A) events, 8 vaccinations, information regarding psychological, locomotor and puberty development, additional treatment, care and education. Additional laboratory results collected for children comprise HIV DNA and additional viral infections.
Patient and public involvement
The community of people living with HIV in the Netherlands, represented by the Dutch Association of People Living with HIV (HIV Vereniging), together with healthcare providers and policy makers was closely involved in the establishment and setting-up of the ATHENA cohort in 1997 to monitor the effectiveness of providing early access to life-saving PI containing combination therapy by the Minister of Health. The involvement of the Dutch Association of People Living with HIV continues to the present, with the association being represented on both SHM's Governing Board and Scientific Advisory Board. Findings from the ATHENA cohort are published annually in the HIV Monitoring Report, which is publicly accessible through our website (https://www. hiv-monitoring. nl/ english/ research/ monitoringreports/). Each year, the Dutch Association of People Living with HIV, together with other stakeholders, are asked for input on a press release by SHM in which key findings from the annual report are publicly disseminated.
FIndIngs to dAte
Since 2001, 1 the ATHENA cohort provides a comprehensive overview of the trends over time in the HIV epidemic in the Netherlands including the impact of antiretroviral treatment (https://www. hiv-monitoring. nl/ english/ research/ monitoringreports/). Furthermore, it has advanced our knowledge of HIV-associated comorbidities and coinfections, as well as insight on the spread and prevention of HIV. In addition, a complete and up-to-date list of scientific publications is available online (https://www. hiv-monitoring. nl/ english/ research/ publications/).
Participant characteristics
On 1 January 2017, 19 035 HIV-1-positive participants were known to be in HIV care: 18 824 were aged 18 years or older Open access and 211 were below 18 years of age (table 2). The remaining 6001 participants were no longer in care because they had died (n=2776; 46%), were lost to care (n=1734; 29%) or had moved abroad (n=1491; 25%).
the hIV epidemic in the netherlands
The ATHENA cohort has generated many insights into the evolution of the Dutch HIV epidemic over time, including information on diagnosed, and estimates of as yet undiag-
2 Although the overall rate of late presentation has also been declining, 10 targeted programmes to reduce late HIV diagnoses remain needed for all risk groups and should be prioritised for heterosexual males and females, migrants from South and Southeast Asia and sub-Saharan Africa, people over 50 years of age and certain regions in the Netherlands. 2 Studies combining modelling and phylogenetic analysis have shown that HIV transmission among MSM can be averted if men undergo annual HIV testing and, if found to be HIV positive, immediately initiate cART, or, if found to be HIV-negative, half of these men who are perceived to be at high-risk for HIV acquisition initiate pre-exposure antiretroviral prophylaxis. 14 response to cArt In the early 2000s, ATHENA generated additional evidence that cART was efficacious for the treatment of HIV and provided insight into CD4 cell count and viral load dynamics in both treated and untreated HIV infection. [15] [16] [17] In recent years, initiation of cART following an HIV diagnosis has been taking place increasingly earlier and irrespective of CD4 cell count. By 2016, the median CD4 cell count at start of cART had increased to 410 cells/mm 3 , and the majority of people starting cART did so within 1 month of diagnosis (figure 2). At the same time, the time spent on a first-line regimen is increasing, and both short-term and long-term virological suppression rates are high and continue to improve. Since 2000, the annual proportion of individuals on cART with a viral load >200 copies/mL has decreased to approximately 3%. Consequently, earlier diagnosis in combination with immediate treatment and very low rates of virological failure on treatment have contributed to a substantial decrease in the annual number of new HIV diagnoses among MSM in the Netherlands, despite an increase in risk behaviour. 18 19 Among adults who do experience virological failure, the rate of acquired drug resistance remains low and continues to decline over time. 2 20 The overall prevalence of transmitted resistance remains low over time, in line with European surveillance data. 21 trends in morbidity and mortality over time Since cART became available, AIDS-related deaths have decreased dramatically and life-expectancy has improved substantially. 22 23 Moreover, data from the cohort led to the Netherlands becoming one of the first countries where HIV-positive people could get life insurance. 24 The limited and decreasing number of individuals who still die of AIDS each year mainly consist of those presenting late for care.
As a result of both increased life expectancy in people living with HIV, as well as an increase in age at HIV diagnosis, the HIV-positive population in the Netherlands is ageing ( figure 3 ). Modelling studies have provided insight into the expected disease burden resulting from this age shift. By 2030, an estimated 73% of the HIV-positive population in the Netherlands will be aged 50 years or older, and 84% of HIV-positive people are expected to have at least one non-communicable disease (up from 29% in 2010). 25 Consequently, the annual cardiovascular disease incidence and costs are predicted to increase between 2015 and 2030. However, traditional cardiovascular disease prevention interventions can optimise cardiovascular health and avert future costs, particularly if targeting high-risk individuals. 26 
Continuum of care
The Netherlands is well on its way to reaching the UNAIDS 90-90-90 targets for 2020, 27 and Amsterdam is among the first cities to have reached and exceeded these targets. 28 In 2016, an estimated 89% of all people living with HIV in the Netherlands were diagnosed and linked to care, 92% of these people were on cART and 95% of those on cART had a suppressed viral load (figure 4). Although time from acquiring HIV to reaching viral suppression has declined over time, further decline continues to be challenged mainly by the duration of undiagnosed HIV infection.
29
Pregnant women, children and adolescents The combination of opt-out HIV screening and use of cART in HIV-positive pregnant women has reduced the risk of mother-to-child transmission to <1% in the Netherlands. 2 At the same time, an increasing number of children who acquired HIV through vertical transmission are being adopted from sub-Saharan Africa by Dutch parents. In general, paediatric HIV care has resulted in favourable treatment outcomes, and viral suppression among children has improved substantially over time. 30 Of note, however, is that adolescents and young adults are particularly vulnerable to virological failure, especially around and shortly Open access after the moment of transition from paediatric to adult care.
Open access
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Viral hepatitis coinfection HBV and HCV coinfections are relatively common among HIV-positive people and are closely monitored in the cohort. 2 However, phylogenetic analysis has shown limited overlap between HCV and HIV transmission networks, which indicates a dynamic sexual network structure of Dutch HIV-positive MSM. 32 Up to 2016, an increase in the prevalence of active HCV (presence of detectable HCV RNA) was reported, especially among MSM. Since the introduction and reimbursement of direct-acting antiviral agents for HCV treatment in 2014, increasing numbers of HIV-positive people with both acute and chronic HCV coinfection have been treated for, and successfully cured of, HCV (ie, sustained virological response) (figure 5). 2 33 This has resulted in a rapidly declining number of coinfected individuals in HIV care who still need to be cured of HCV.
strengths And lIMItAtIons
The unique strength of the cohort is its completeness, both in terms of coverage (ie, 98% of all HIV-positive people in care in the Netherlands), as well as the quality and extensiveness of the data collection. 34 Furthermore, follow-up and data collection continues uninterrupted for children who transfer from paediatric to adult HIV care and for people who transfer to another HIV treatment centre within the Netherlands.
To improve data quality, SHM has developed a quality management system based on the principals of a plan-docheck-adjust cycle. New data collectors receive intensive training and follow a personal coaching programme. SHM also has an internal helpdesk that resolves questions from the data collectors. After collection, the data are automatically checked for inconsistencies and source-verified by the data management and quality control departments. Hepatitis C continuum of care. Legend: out of a total of 1883 individuals linked to HIV care and diagnosed with HCV, 1439 individuals (76%) were retained in care, and of these 1439, 1302 (90%) had ever received treatment for HCV. Of the 1302 individuals treated for HCV, 1247 (96%) had completed HCV treatment and had data available to calculate their HCV treatment response. Overall, 1137 of the 1247 (91%) individuals who completed treatment had achieved an SVR. As a result, 302 of the 1439 individuals (21%) who were alive and in care as of 1 May 2017 in one of the Dutch HIV treatment centres remained untreated (n=137), not successfully treated (n=85), were still being treated or had insufficient time after treatment discontinuation to allow SVR calculation (n=80). All 80 individuals in whom SVR could not yet be calculated due to insufficient time since treatment discontinuation had been treated with novel direct-acting antiviral agents combinations. For that reason, we extrapolated the observed direct-acting antiviral agents SVR rate of 97% and assumed that 97% of these 80 individuals (n=77) will eventually be successfully treated. This resulted in an estimated number of 302-77=225 individuals who remain untreated or unsuccessfully treated. SVR, sustained virological response (ie, HCV cure).
Open access (ACS) 36 ; the MSM Observational Study of Acute Infection with Hepatitis C (MOSAIC) 32 ; Co-morbidity and Ageing with HIV (AGE h IV) cohort study 37 ; EU-funded Co-morbidity in Relation to AIDS (COBRA) programme 38 ; and the HIV Transmission Elimination Amsterdam (H-TEAM) initiative. 39 ATHENA collaborates with other research groups and observational cohorts in western Europe, the USA and Canada. Data sharing and collaboration has taken place or is ongoing with the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), 40 EuroSIDA, 41 the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) 42 ; Bridging the Evolution and Epidemiology of HIV in Europe (BEEHIVE) 47 ; HIV Resistance Response Database Initiative (RDI) 48 49 ; and International epidemiology Databases to Evaluate AIDS (IeDEA). 50 A limitation of the cohort is that the data are based on medical records and not on scheduled data collection through questionnaires. While the data collection protocol is structured, the availability of the data depends on the frequency of patient visits and the completeness and detail of the notes in the medical record. Although this provides insight into routine HIV care in a 'real life' setting, some aspects of HIV care and disease progression might go unmeasured and therefore unnoticed. Data collection largely depends on information captured by the medical records of HIV physicians and HIV nurse consultants. This potentially limits obtaining more detailed data regarding less severe comorbid conditions and substance use, which may not be brought to the attention of the HIV physician. Furthermore, while the cohort captures 98% of all people in HIV care, we do not know well which (eg, migrants) and how many people do not enter HIV care. Another limitation is that HIV genotype sequence data are incomplete and not available from all cohort participants.
CollAborAtIon HIV physicians can review the data of their own treatment centre and compare these data with the full cohort through an online report builder. Statistical information or data for own research purposes can be requested by submitting a research proposal (https:// www. hiv-monitoring. nl/ english/ research/ researchprojects/). For correspondence: hiv. monitoring@ amc. uva. nl.
